Proteasomal adaptations to FDA-approved proteasome inhibitors: a potential mechanism for drug resistance?

le Kim, Kyung Bo
Foilsithe in Cancer Drug Resist (2021)

Chemical Genetics: Exploring the Role of the Proteasome in Cell Biology Using Natural Products and Other Small Molecule Proteasome Inhibitors

le Kim, Kyung Bo, Crews, Craig M.
Foilsithe 2008

Activity-Based Imaging Probes of the Proteasome

le Carmony, Kimberly Cornish, Kim, Kyung Bo
Foilsithe 2013

From Epoxomicin to Carfilzomib: Chemistry, Biology, and Medical Outcomes

le Kim, Kyung Bo, Crews, Craig M.
Foilsithe 2013

PROTAC-Induced Proteolytic Targeting

le Carmony, Kimberly Cornish, Kim, Kyung-Bo
Foilsithe 2012

High-Resolution Snapshots of Proteasome Inhibitors In Action Revise Inhibition Paradigms and Inspire Next-Generation Inhibitor Design

le Carmony, Kimberly, Lee, Wooin, Kim, Kyung Bo
Foilsithe in Chembiochem (2016)

The Ubiquitin-Proteasome Pathway and Proteasome Inhibitors

le Myung, Jayhyuk, Kim, Kyung Bo, Crews, Craig M.
Foilsithe 2001

Development and Characterization of Proteasome Inhibitors

le Kim, Kyung Bo, Fonseca, Fabiana N., Crews, Craig M.
Foilsithe 2005

Inhibitors of the Immunoproteasome: Current Status and Future Directions

le Miller, Zachary, Ao, Lin, Kim, Kyung Bo, Lee, Wooin
Foilsithe 2013

Optimization of Naltrexone Diclofenac Codrugs for Sustained Drug Delivery Across Microneedle-Treated Skin

le Ghosh, Priyanka, Lee, DoMin, Kim, Kyung Bo, Stinchcomb, Audra L.
Foilsithe 2013

Selective Immunoproteasome Inhibitors with Non-Peptide Scaffolds Identified from Structure-Based Virtual Screening

le Kasam, Vinod, Lee, Na-Ra, Kim, Kyung-Bo, Zhan, Chang-Guo
Foilsithe 2014

Nitric oxide-dependent CYP2B degradation is potentiated by a cytokine-regulated pathway and utilizes the immunoproteasome subunit LMP2

le Sun, Haiyan, Lee, Choon-myung, Tripathi, Shweta, Kim, Kyung-Bo, Morgan, Edward T.
Foilsithe 2012

Two-headed PROTAC: An effective New Tool for Targeted Protein Degradation

le Cyrus, Kedra, Wehenkel, Marie, Choi, Eun-Young, Swanson, Hollie, Kim, Kyung-Bo
Foilsithe 2010

Next-generation proteasome inhibitors for cancer therapy

le Park, Ji Eun, Miller, Zachary, Jun, Yearin, Lee, Wooin, Kim, Kyung Bo
Foilsithe in Transl Res (2018)

Jostling for Position: Optimizing Linker Location in the Design of Estrogen Receptor-targeting PROTACs

le Cyrus, Kedra, Wehenkel, Marie, Choi, Eun-Young, Lee, Hyosung, Swanson, Hollie, Kim, Kyung-Bo
Foilsithe 2010

LMP2-Specific Inhibitors: Chemical Genetic Tools for Proteasome Biology

le Ho, Yik Khuan (Abby), Bargagna-Mohan, Paola, Wehenkel, Marie, Mohan, Royce, Kim, Kyung-Bo
Foilsithe in Chem Biol (2007)

Development of Novel CH223191-Based Antagonists of the Aryl Hydrocarbon Receptor

le Choi, Eun-Young, Lee, Hyosung, Dingle, R. W. Cameron, Kim, Kyung Bo, Swanson, Hollie I.
Foilsithe 2012

Polymer Micelle Formulations of Proteasome Inhibitor Carfilzomib for Improved Metabolic Stability and Anticancer Efficacy in Human Multiple Myeloma and Lung Cancer Cell Lines

le Ao, Lin, Reichel, Derek, Hu, Di, Jeong, Hyunyoung, Kim, Kyung Bo, Bae, Younsoo, Lee, Wooin
Foilsithe in J Pharmacol Exp Ther (2015)

H727 cells are inherently resistant to the proteasome inhibitor carfilzomib, yet require proteasome activity for cell survival and growth

le Lee, Min Jae, Miller, Zachary, Park, Ji Eun, Bhattarai, Deepak, Lee, Wooin, Kim, Kyung Bo
Foilsithe in Sci Rep (2019)

Impact of linker length on the activity of PROTACs

le Cyrus, Kedra, Wehenkel, Marie, Choi, Eun-Young, Han, Hyeong-Jun, Lee, Hyosung, Swanson, Hollie, Kim, Kyung-Bo
Foilsithe 2010